```
=> s l1
SAMPLE SEARCH INITIATED 11:59:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    96966 TO ITERATE

  2.1% PROCESSED     2000 ITERATIONS                                  0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      1920831 TO  1957809
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=>
Uploading C:\Documents and Settings\EBernhardt\My
Documents\Stnexp\Queries\10539372-2.str
```



```
chain nodes :
1  2  3  4  5  6  7  8  9  11  12  13  15  44
ring nodes :
16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36
37  38
ring/chain nodes :
14
chain bonds :
1-11  1-9  1-8  1-44  2-3  2-11  3-4  3-12  3-13  4-5  4-14  5-6  6-7  6-15
```

```
ring bonds :
16-17  16-20  17-18  18-19  19-20  21-22  21-26  22-23  23-24  24-25  25-26  27-28
27-32  28-29  29-30  30-31  31-32  33-34  33-38  34-35  35-36  36-37  37-38
exact/norm bonds :
1-11  1-44  2-3  2-11  4-5  5-6  6-7  6-15  16-17  16-20  17-18  18-19  19-20
21-22  21-26  22-23  23-24  24-25  25-26  27-28  27-32  28-29  29-30  30-31  31-32
33-34  33-38  34-35  35-36  36-37  37-38
exact bonds :
1-9  1-8  3-4  3-12  3-13  4-14


G1:C,O,N

G2:[*1],[*2],[*3],[*4]

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
 20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  44:CLASS
Generic attributes :
15:
Saturation             : Unsaturated




L3      STRUCTURE UPLOADED

=> s l3
SAMPLE SEARCH INITIATED 12:07:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    43107 TO ITERATE

  4.6% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       849741 TO   874539
PROJECTED ANSWERS:               0 TO        0

L4            0 SEA SSS SAM L3

=> s l3 sss full
FULL SEARCH INITIATED 12:07:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   862126 TO ITERATE

 95.8% PROCESSED   825571 ITERATIONS                                84 ANSWERS

100.0% PROCESSED   862126 ITERATIONS                                86 ANSWERS
SEARCH TIME: 00.00.24

L5           86 SEA SSS FUL L3
```

```
=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.40     178.61

FILE 'CAPLUS' ENTERED AT 12:07:46 ON 27 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Dec 2007  VOL 147 ISS 26
FILE LAST UPDATED: 26 Dec 2007  (20071226/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l5
L6          22 L5

=> d l6 1-22 bib abs hitstr

L6   ANSWER 1 OF 22  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2007:705111  CAPLUS
DN   147:143660
TI   Preparation of 3-chloro-4-isopropoxybenzamide and 3-cyano-4-
     isopropoxybenzamide derivatives as inhibitors of mitotic kinesins
IN   Qian, Xiangping; Ashcraft, Luke W.; Wang, Jianchao; Yao, Bing; Jiang,
     Hong; Bergnes, Gustave; Morgan, Bradley P.; Morgans, David J.; Dhanak,
     Dashyant; Knight, Steven D.; Adams, Nicholas D.; Parrish, Cynthia A.;
     Duffy, Kevin J.; Fitch, Duke; Tedesco, Rosanna
PA   USA
SO   U.S. Pat. Appl. Publ., 171pp., Cont.-in-part of U.S. Ser. No. 271,147.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 4
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 2007149516        A1    20070628    US 2006-598250         20061108
     US 2006247289        A1    20061102    US 2005-271147         20051109
PRAI US 2005-271147       A2    20051109
     US 2004-569510P      P     20040506
     US 2005-121709       A2    20050503
     US 2005-124608       A2    20050506
```

OS MARPAT 147:143660
GI



I



III

AB The title compds. [I; R1 = 3-halo-4-((R)-1,1,1-trifluoropropan-2-yloxy)phenyl, 3-cyano-4-((R)-1,1,1-trifluoropropan-2-yloxy)phenyl, 3-halo-4-isopropylaminophenyl, 3-cyano-4-isopropylaminophenyl, 3-halo-4-((R)-1,1,1-trifluoropropan-2-ylamino)phenyl, 3-cyano-4-((R)-1,1,1-trifluoropropan-2-ylamino)phenyl; X = CO, SO2; R2 = H, (un)substituted lower alkyl; W = CR4, CH2CR4, N; R3 = COR7, H, each (un)substituted substituted alkyl, heterocycloalkyl, heteroaryl, or aryl, cyano, sulfonyl; R4 = H, (un)substituted alkyl; R5 = H, HO, each (un)substituted amino, cycloalkyl, heterocycloalkyl, heteroaryl, or lower alkyl; R6 = H, CONH2, (un)substituted alkyl, alkoxy, aryloxy, heteroaryloxy, alkoxycarbonyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; R7 = HO, each (un)substituted lower alkyl, aryl, amino, aralkoxy, or alkoxy; provided that if W is N, then R5 is not hydroxy or (un)substituted amino, and R6 is not optionally substituted alkoxy, optionally substituted aralkoxy, optionally substituted heteroaralkoxy, or optionally substituted amino] are prepared (1R)-1-(methoxycarbonylamino)-1-[4-[4-[(2S)-2-[[[4-(((1R)-2,2,2-trifluoroisopropyl)oxy)-3-chlorophenyl]carbonyl]amino]-4-hydroxybutyl]phenyl]-1-ethylimidazol-2-yl]ethane. These compds. including N-benzoyl-amino alcs., N-benzoyl-amino acid amide, N-benzoylsemicarbazide, and N-benzoyl-diamine derivs. are inhibitors of one or more mitotic kinesins and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, fungal disorders, and inflammation by modulating the activity of one or more mitotic kinesins. Thus, cyclocondensation of (2S)-2-(tert-butoxycarbonylamino)-5-bromo-4-oxopentanoic acid Me ester with thiobenzamide in the presence of diisopropylethylamine in methanol under refluxing for 24 h gave (2S)-2-(tert-butoxycarbonylamino)-3-(2-phenylthiazol-4-yl)propanoic acid which was treated with CF3CO2H in CH2Cl2 at room temperature for 10 min to give (2S)-2-amino-3-(2-phenylthiazol-4-yl)propanoic acid (II). II was condensed with 3-chloro-4-isopropoxybenzoic acid pentafluorophenyl ester in the presence of diisopropylethylamine in DMF at room temperature to give (2S)-N-methyl-2-[(3-chloro-4-isopropoxybenzoyl)amino]-3-(2-phenylthiazol-4-yl)propanamide (III). Many of the compds. I showed GI50 (50% growth inhibition concentration) of ≤10 μM against human ovarian tumor cells Skov-3.

IT 943297-47-0P, N-[(2S)-2-[[[3-Chloro-4-(1-methylethoxy)phenyl]carbonyl]amino]-3-[4-[8-(1-hydroxyethyl)-4-

hydroimidazo[1,2-a]pyridin-2-yl]phenyl]propyl]-2-(pyrrolidin-1-yl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-benzoyl amino alcs., N-benzoyl-amino acid, N-benzoylsemicarbazide derivs. as inhibitors of mitotic kinesins)
RN 943297-47-0 CAPLUS
CN 1-Pyrrolidineacetamide, N-[(2S)-2-[[3-chloro-4-(1-methylethoxy)benzoyl]amino]-3-[4-[8-(1-hydroxyethyl)imidazo[1,2-a]pyridin-2-yl]phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:863107 CAPLUS
DN 142:48476
TI Nocathiacin I analogues: synthesis, in vitro and in vivo biological activity of novel semi-synthetic thiazolyl peptide antibiotics
AU Naidu, B. Narasimhulu; Sorenson, Margaret E.; Zhang, Yunhui; Kim, Oak K.; Matiskella, John D.; Wichtowski, John A.; Connolly, Timothy P.; Li, Wenying; Lam, Kin S.; Bronson, Joanne J.; Pucci, Michael J.; Clark, Junius M.; Ueda, Yasutsugu
CS The Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(22), 5573-5577
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 142:48476
AB Several nocathiacin I analogs were synthesized and evaluated for their antibacterial activity. Most of these semi-synthetic analogs retained very good in vitro and in vivo antibacterial activity of nocathiacin I.
IT 807342-65-0P 807342-68-3P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and in vitro and in vivo biol. activity of novel semi-synthetic thiazolyl peptide antibiotics nocathiacin I analogs in relation to aqueous solubility)

RN 807342-65-0 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-amino-1-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-2-oxoethyl]-2-[(11S,14E,21S,22S,33S,49S)-9,10,11,12,13,14,19,20,21,22,29,30,32,33-tetradecahydro-3,29-dihydroxy-11-[(1R)-1-hydroxyethyl]-14-(1-methoxyethylidene)-9,12,19,30,40,48-hexaoxo-49-[[2,4,6-trideoxy-4-(dimethylamino)-3-C-methyl-α-L-lyxo-hexopyranosyl]oxy]-22,25-(ethanoxymethano)-8,5:18,15:37,34-trinitrilo-21,33-([2,4]-endo-thiazolomethanimino)-5H,15H,24H,34H-pyrido[3',2':20,21][1,28,8,18,24,4,11,14]dioxatrithiatriazacyclodotriacontino[30,31-b]indol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



RN 807342-68-3 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-1-[[methyl[2-(1-piperidinyl)ethyl]amino]methyl]-2-oxoethyl]-2-[(11S,14E,21S,22S,33S,49S)-9,10,11,12,13,14,19,20,21,22,29,30,32,33-tetradecahydro-3,29-dihydroxy-11-[(1R)-1-hydroxyethyl]-14-(1-methoxyethylidene)-9,12,19,30,40,48-hexaoxo-49-[[2,4,6-trideoxy-4-(dimethylamino)-3-C-methyl-α-L-lyxo-hexopyranosyl]oxy]-22,25-(ethanoxymethano)-8,5:18,15:37,34-trinitrilo-21,33-([2,4]-endo-thiazolomethanimino)-5H,15H,24H,34H-pyrido[3',2':20,21][1,28,8,18,24,4,11,14]dioxatrithiatriazacyclodotriacontino[30,31-b]indol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:830103 CAPLUS
DN 142:1066
TI Centrally Acting and Metabolically Stable Thyrotropin-Releasing Hormone Analogues by Replacement of Histidine with Substituted Pyridinium
AU Prokai, Laszlo; Prokai-Tatrai, Katalin; Zharikova, Alevtina D.; Nguyen, Vien; Perjesi, Pal; Stevens, Stanley M., Jr.
CS Department of Medicinal Chemistry, University of Florida, Gainesville, FL, 32610, USA
SO Journal of Medicinal Chemistry (2004), 47(24), 6025-6033
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English

OS CASREACT 142:1066

AB Metabolically stable and centrally acting TSH-releasing hormone (TRH) analogs were designed by replacing the central histidine with substituted pyridinium moieties. Their analeptic and acetylcholine-releasing actions were evaluated to assess their potency as central nervous system (CNS) agents. A strong exptl. connection between these two CNS-mediated actions of the TRH analogs was obtained in subject animals. The analog 3-(aminocarbonyl)-1-(3-[2-(aminocarbonyl)pyrrolidin-1-yl]-3-oxo-2-{[(5-oxopyrrolidin-2-yl)carbonyl]amino}propyl)pyridinium (1a) showed the highest (TRH-equivalent) potency and longest, dose-dependent duration of action from a series of homologous compds. in antagonizing pentobarbital-induced narcosis when administered i.v. in its CNS-permeable prodrug form (2a) obtained via reduction of the pyridinium moiety to the nonionic dihydropyridine. The maximum change in hippocampal acetylcholine concentration upon perfusion of the pyridinium-containing tripeptides into the hippocampus of rats was also achieved with 1a. No binding to the endocrine TRH receptor was measured for the TRH analogs reported here; therefore, our design afforded a novel lead for centrally acting TRH analogs. We have also demonstrated the benefits of the prodrug approach on the pharmacokinetics and brain uptake/retention of pyridinium-containing TRH analogs (measured by in vivo microdialysis sampling) upon systemic administration.

IT 797054-98-9P
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of centrally acting and metabolically stable TSH-releasing hormone analogs by replacement of histidine with substituted pyridinium)

RN 797054-98-9 CAPLUS

CN L-Prolinamide, 5-oxo-L-prolyl-6-[3-(aminocarbonyl)pyridinio]-L-norleucyl-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 738575-25-2
CMF C22 H31 N6 O5

Absolute stereochemistry.





CM 2

CRN 14477-72-6
CMF C2 F3 O2



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:610055 CAPLUS
DN 141:157473
TI Preparation of amino acid derivatives as antibacterial agents
IN Anderson, Neils H.; Bowman, Jason; Erwin, Alice; Harwood, Eric; Kline, Toni; Mdluli, Khisimuzi; Ng, Simon; Pfister, Keith B.; Shawar, Ribhi; Wagman, Allan; Yabannavar, Asha
PA Chiron Corporation, USA
SO PCT Int. Appl., 324 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004062601	A2	20040729	WO 2004-US433	20040108
	WO 2004062601	A3	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ

AU	2004204760	A1	20040729	AU 2004-204760	20040108
CA	2512582	A1	20040729	CA 2004-2512582	20040108
US	2004229955	A1	20041118	US 2004-754928	20040108
EP	1618087	A2	20060125	EP 2004-700887	20040108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN	1777577	A	20060524	CN 2004-80005935	20040108
JP	2006519772	T	20060831	JP 2006-500858	20040108
MX	2005PA07394	A	20050912	MX 2005-PA7394	20050707
IN	2005KN01343	A	20060915	IN 2005-KN1343	20050712
US	2006154988	A1	20060713	US 2005-187708	20050722
US	2007244197	A1	20071018	US 2006-417346	20060503
PRAI US	2003-438523P	P	20030108		
US	2003-466974P	P	20030430		
US	2003-520211P	P	20031113		
US	2004-754928	A1	20040108		
WO	2004-US433	W	20040108		

OS MARPAT 141:157473

GI



I



II

AB Title compds. I [E = absent or H, (un)substituted-alkyl, -alkenyl, -aryl, etc.; L = absent or CONH, NHCO, (un)substituted alkyl, etc.; D = absent or (un)substituted-cycloalkyl, -aryl, -heterocyclyl or -heteroaryl; G = absent or alkene, alkyne, CO, etc.; Y = (un)substituted-cycloalkyl, -aryl, -heterocyclyl or -heteroaryl; X = CO, alkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, methylene, or when B is absent X and A together form heterocyclic ring; B = absent or substituted aminoalkylcarbonyl; R3 = H or (un)substituted alkyl, or R3 and A together form a cycloalkyl or heterocyclic ring; R4 = H or (un)substituted alkyl, or R4 and A together form a heterocyclic ring; n = 0-2; A = H, acetylene, alkyl, etc.; Q = absent or substituted amide, SH, SO2NH2, CO2H, etc.] are disclosed: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compns. comprising such compds.; methods of treating bacterial infections by the administration of such compds.; and processes for the preparation of the compds. Thus, e.g., II was prepared via

amidation of 3-bromo-4-fluorobenzoic acid with L-threonine Me ester hydrochloride followed by substitution with hydroxylamine hydrochloride. This invention pertains generally to treating infections caused by gram-neg. bacteria. More specifically, the invention described pertains to treating gram-neg. infections by inhibiting activity of UDP-3-O-(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC). Many of I displayed an IC50 value of less than 10 μM with respect to inhibition of LpxC.

IT 728872-42-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of amino acid derivs. as antibacterial agents)

RN 728872-42-2 CAPLUS
CN 1-Piperazineacetamide, N-[(2S)-3-(hydroxyamino)-3-oxo-2-[[4-(phenylethynyl)benzoyl]amino]propyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:589539 CAPLUS
DN 141:123573
TI Preparation of (hetero)arylcarboxamides as factor Xa inhibitors
IN Liebeschuetz, John Walter; Sheehan, Scott Martin; Watson, Brian Morgan
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004060872	A1	20040722	WO 2003-US39101	20031222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003296393 A1 20040729 AU 2003-296393 20031222
EP 1581493 A1 20051005 EP 2003-814680 20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006052606 A1 20060309 US 2005-539372 20050616
PRAI US 2002-436625P P 20021230
WO 2003-US39101 W 20031222
OS MARPAT 141:123573
GI



I



II

AB Compds. of formula I [R1 = pyrrolidinyl, (substituted) piperidinyl, (substituted) piperazinyl; R2 = (substituted) Ph, indolyl or benzothiophenyl; R3 = (substituted) Ph, pyridyl, furyl, naphthyl, cycloalkyl, alkyl, etc.; Z = CH2, O, (substituted) NH; n = 1-3] are prepared as inhibitors of the serine protease Factor Xa and are useful in the treatment of thrombotic disorders. Thus, II was prepared in several steps. The prepared compds. had Kass values > 1 x 106 L/mol in the enzyme inhibition assay.

IT 724463-08-5P 724463-09-6P 724463-10-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (hetero)arylcarboxamides as factor Xa inhibitors)

RN 724463-08-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-1-phenyl-2-[2-(4-piperidinyl)ethoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 724463-09-6 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-2-[2-(1-methyl-4-piperidinyl)ethoxy]-1-phenylethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 724463-10-9 CAPLUS
CN 1H-Indole-6-carboxamide, 3-chloro-N-[(1R)-1-phenyl-2-[3-(4-piperidinyl)propoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 724463-63-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (hetero)arylcarboxamides as factor Xa inhibitors)
RN 724463-63-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[2-[(2R)-2-[[(3-chloro-1H-indol-6-yl)carbonyl]amino]-2-phenylethoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:308415 CAPLUS
DN 140:321240
TI Preparation of lactam-containing diaminoalkanes, β-amino acids, α-amino acids and derivatives thereof as factor Xa inhibitors
IN Qiao, Jennifer X.; Han, Wei
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031145	A2	20040415	WO 2003-US31079	20031001
	WO 2004031145	A3	20040701		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004077635	A1	20040422	US 2003-677063	20031001
	AU 2003279735	A1	20040423	AU 2003-279735	20031001
	EP 1558606	A2	20050803	EP 2003-773077	20031001
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2007129361	A1	20070607	US 2007-622484	20070112
PRAI	US 2002-415366P	P	20021002		
	US 2002-417208P	P	20021009		
	US 2003-677063	A1	20031001		
	WO 2003-US31079	W	20031001		

OS MARPAT 140:321240
GI



II



III



IV



V

AB The title compds. PMM1 [I; one of P and M1 = G and the other -AB; G = II, III (wherein ring D, including the two carbon atoms of ring E to which it is attached, is (un)substituted 5-6 membered ring consisting of carbon atoms and 0-3 heteroatoms selected from N, O, S(O)0-2; ring D may contain 0-3 ring double bonds; ring E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; alternatively, ring D is absent); M = (un)substituted 3-8 membered linear chain consisting of carbon atoms, carbonyl groups, thiocarbonyl, heteroatoms, and there are 0-2 double bonds and 0-1 triple bond; A = (un)substituted carbocycle, 5-12 membered heterocycle; B = IV (wherein Q1 = CO, SO2; ring Q = (un)substituted 4-8 membered monocyclic or bicyclic ring optionally containing optionally heteroatoms, and optionally fused, etc.; X = absent, CO, SO, SO2, etc.)], useful as inhibitors of trypsin-like serine proteases, specifically factor Xa for treating thromboembolic disorder, were prepared E.g., a 3-step synthesis of V, starting from 1-(4-aminophenyl)-1H-pyridin-2-one and Boc-DL-PHG-OH, was given. The number of compds. I were found to exhibit Ki's of ≤ 10 μM against human factor Xa. The pharmaceutical composition comprising the compound I is claimed.

IT 678175-26-3P 678175-27-4P 678175-33-2P
678175-64-9P 678175-65-0P 678175-70-7P
678176-04-0P 678176-05-1P 678176-10-8P
678176-56-2P 678176-57-3P 678176-62-0P
678176-96-0P 678177-12-3P 678177-13-4P
678177-25-8P 678177-41-8P 678177-42-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lactam-containing diaminoalkanes, β-amino acids, α-amino acids and derivs. thereof as factor Xa inhibitors for treating thromboembolic disorder)

RN 678175-26-3 CAPLUS

CN Benzamide, N-[3-[(4-chlorophenyl)amino]-1-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1(2H)-pyridinyl)- (CA INDEX NAME)



RN 678175-27-4 CAPLUS
CN Benzamide, N-[3-[(4-chlorophenyl)amino]-1-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1(2H)-pyridinyl)- (CA INDEX NAME)



RN 678175-33-2 CAPLUS
CN Benzamide, N-[3-[(4-chlorophenyl)amino]-1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-3-oxopropyl]-4-(2-oxo-1(2H)-pyridinyl)- (CA INDEX NAME)



RN 678175-64-9 CAPLUS
CN Benzamide, N-[3-[(5-chloro-2-pyridinyl)amino]-1-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1(2H)-pyridinyl)-(CA INDEX NAME)



RN 678175-65-0 CAPLUS
CN Benzamide, N-[3-[(5-chloro-2-pyridinyl)amino]-1-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1(2H)-pyridinyl)-(CA INDEX NAME)



RN 678175-70-7 CAPLUS
CN Benzamide, N-[3-[(5-chloro-2-pyridinyl)amino]-1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-3-oxopropyl]-4-(2-oxo-1(2H)-pyridinyl)- (CA INDEX NAME)



RN 678176-04-0 CAPLUS
CN Benzamide, N-[3-[(4-chlorophenyl)amino]-1-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1-piperidinyl)- (CA INDEX NAME)



RN 678176-05-1 CAPLUS
CN Benzamide, N-[3-[(4-chlorophenyl)amino]-1-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1-piperidinyl)- (CA INDEX NAME)



RN 678176-10-8 CAPLUS
CN Benzamide, N-[3-[(4-chlorophenyl)amino]-1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-3-oxopropyl]-4-(2-oxo-1-piperidinyl)- (CA INDEX NAME)



RN 678176-56-2 CAPLUS
CN Benzamide, N-[3-[(5-chloro-2-pyridinyl)amino]-1-[[[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1-piperidinyl)- (CA INDEX NAME)



RN 678176-57-3 CAPLUS
CN Benzamide, N-[3-[(5-chloro-2-pyridinyl)amino]-1-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-3-oxopropyl]-4-(2-oxo-1-piperidinyl)- (CA INDEX NAME)



RN 678176-62-0 CAPLUS
CN Benzamide, N-[3-[(5-chloro-2-pyridinyl)amino]-1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-3-oxopropyl]-4-(2-oxo-1-piperidinyl)- (CA INDEX NAME)



RN 678176-96-0 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[3-[2-(2-oxo-1-piperidinyl)ethoxy]-2-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]propyl]- (CA INDEX NAME)



RN 678177-12-3 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-2-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]ethyl]- (CA INDEX NAME)



RN 678177-13-4 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-2-[[4-(2-oxo-1(2H)-pyridinyl)benzoyl]amino]ethyl]- (CA INDEX NAME)



RN 678177-25-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[2-[[4-(2-oxo-1-piperidinyl)benzoyl]amino]-3-[2-(2-oxo-1-piperidinyl)ethoxy]propyl]- (CA INDEX NAME)



RN 678177-41-8 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[2-(4-methyl-1-piperazinyl)ethoxy]methyl]-2-[[4-(2-oxo-1-piperidinyl)benzoyl]amino]ethyl]- (CA INDEX NAME)



RN 678177-42-9 CAPLUS
CN 2-Thiophenecarboxamide, 5-chloro-N-[1-[[methyl[2-(4-methyl-1-piperazinyl)ethyl]amino]methyl]-2-[[4-(2-oxo-1-piperidinyl)benzoyl]amino]ethyl]- (CA INDEX NAME)



L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:182658 CAPLUS
DN 140:235738
TI Preparation of pyrazolopyrimidines as calcium receptor modulators
IN Yasuma, Tsuneo; Mori, Akira; Kawase, Masahiro; Kimura, Hiroyuki; Yoshida, Masato; Gyorkos, Albert Charles; Pratt, Scott Alan; Corrette, Christopher Peter

PA Takeda Chemical Industries, Ltd., Japan; Takeda Pharmaceutical Company Limited
SO PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004017908	A2	20040304	WO 2003-US26317	20030821
	WO 2004017908	A3	20060105		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2494700	A1	20040304	CA 2003-2494700	20030821
	AU 2003265585	A1	20040311	AU 2003-265585	20030821
	EP 1572113	A2	20050914	EP 2003-793273	20030821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006510582	T	20060330	JP 2004-529835	20030821
	CN 1771231	A	20060510	CN 2003-823938	20030821
	BR 2003013880	A	20071106	BR 2003-13880	20030821
	US 2006079536	A1	20060413	US 2005-525158	20050222
	IN 2005KN00280	A	20060818	IN 2005-KN280	20050225
	NO 2005001328	A	20050315	NO 2005-1328	20050315
PRAI	US 2002-406012P	P	20020826		
	US 2003-466129P	P	20030428		
	WO 2003-US26317	W	20030821		

OS MARPAT 140:235738
GI



I



II



III



IV

AB The title compds. [I; ring A = (un)substituted 5-7 membered ring; ring B = (un)substituted 5-7 membered heterocyclic ring; X1 = (un)substituted CH, CH2, N or NH; X2 = N or (un)substituted NH; Y = C, (un)substituted CH or N; Z = (un)substituted CH, CH2, N or NH; Ar = (un)substituted cyclic group; R = H, (un)substituted alkyl, etc.; and their salts], useful as calcium receptor modulators, were provided. The compds. II, III [wherein ring A = (un)substituted 5-7 membered ring; Q = C, CR5 (R5 = H, alkyl, hydroxyalkyl, etc.), or N; X1 = CR1 (R1 = H, alkyl, hydroxyalkyl, etc.), CR1R2 (R1 as above; R2 = H, heterocyclyl, etc.); R3 = H, alkyl, hydroxyalkyl, aminoalkyl, etc.; Y = C, CR4 (R4 = H, alkyl, hydroxyalkyl, etc.), or N; R8-R12 = H, (un)substituted alkyl, etc.; X3 = a bond, O, (un)oxidized S, N, (un)substituted NH, C1-2 alkylene; or their salts], were also provided. Thus, reacting amidation of the acid IV [R = H] with 4-(F3C)C6H4C(Et)2NH2 afforded 31% IV [R = 4-(F3C)C6H4C(Et)2NH]. Biol. data were given for selected compds. The pharmaceutical composition comprising the compound I is claimed.

IT 667922-27-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as calcium receptor modulators)

RN 667922-27-2 CAPLUS

CN Pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-[1,1-dimethyl-2-[[2-(1-piperidinyl)ethyl]amino]ethyl]-4,5,6,7-tetrahydro-5-phenyl-7-(trifluoromethyl)-, (5R,7S)-rel- (CA INDEX NAME)

Relative stereochemistry.



L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:543696 CAPLUS
DN 137:353286
TI Design, synthesis, and biological evaluation of novel, centrally-acting thyrotropin-releasing hormone analogs
AU Prokai-Tatrai, Katalin; Perjesi, Pal; Zharikova, Alevtina D.; Li, Xiaoxu; Prokai, Laszlo
CS College of Pharmacy, Center for Drug Discovery, University of Florida, Gainesville, FL, 32610-0497, USA
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(16), 2171-2174
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:353286
GI



I

AB Novel, metabolically stable and centrally acting TRH analogs with substituted pyridinium moieties replacing the [His2] residue of the endogenous peptide were prepared by solid-phase Zincke reaction. The 1,4-dihydropyridine prodrugs of these analogs obtained after reducing the pyridinium moiety were able to reach the brain and maintain a sustained concentration of the charged, degradation-resistant analogs formed after enzymic oxidation of the prodrug, as manifested by the analeptic action measured in mice. Among the four analogs reported, compound I showed the highest potency and longest duration of action in reducing the pentobarbital-induced sleeping time compared to the parent TRH. No binding to the endocrine TRH-receptor was measured for I; thus, this

compound emerged as a potent, centrally acting TRH analog.

IT 474520-12-2P
RL: ANT (Analyte); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(solid-phase synthesis, analeptic action, and receptor binding of TSH-releasing hormone pyridine and dihydropyridine analogs)

RN 474520-12-2 CAPLUS

CN L-Prolinamide, 5-oxo-L-prolyl-6-[3-(aminocarbonyl)pyridinio]-L-norleucyl-, chloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:247283 CAPLUS

DN 137:6366

TI A Solid-Phase Synthetic Route to Unnatural Amino Acids with Diverse Side-Chain Substitutions

AU Scott, William L.; O'Donnell, Martin J.; Delgado, Francisca; Alsina, Jordi

CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SO Journal of Organic Chemistry (2002), 67(9), 2960-2969
CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

OS CASREACT 137:6366

AB Reacting imine derivs. of resin-bound amino acids (i.e., 3,4-dichlorobenzaldehyde Schiff bases of Wang resin-bound Ala or Phe) with α,ω-dihaloalkanes provides highly versatile intermediates to racemic α,α-disubstituted amino acids with a wide variety of

side-chain functionality. Two strategies were developed to convert the intermediate ω-chloro or ω-bromo derivs. to the desired products. Together, they allow the creation of amino acids with diverse functionalities (ω-chlorides, nitriles, azides, acetates, thioacetates, thioethers, secondary and tertiary aliphatic amines, and anilines) placed at varying chain lengths (2-5) from the α-center of the amino acid.

IT 433220-56-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of side-chain substituted amino acids by alkylating Schiff bases of Phe- or Ala-Wang resins with dihaloalkanes followed by nucleophilic substitutions)

RN 433220-56-5 CAPLUS

CN 1-Pyrrolidinehexanoic acid, α-methyl-α-[(2-naphthalenylcarbonyl)amino]- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:142742 CAPLUS

DN 136:200481

TI Preparation of water-soluble thiazolyl peptide derivatives

IN Naidu, B. Narasimhulu; Li, Wenying; Lam, Kin S.; Sorenson, Margaret E.; Wichtowski, John A.; Connolly, Timothy P.; Ueda, Yasutsugu; Bronson, Joanne J.; Zhang, Yunhui; Kim, Oak K.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014354	A1	20020221	WO 2001-US25560	20010815
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002065219	A1	20020530	US 2001-928468	20010813
	AU 2001086497	A5	20020225	AU 2001-86497	20010815
PRAI	US 2000-225598P	P	20000815		
	WO 2001-US25560	W	20010815		

OS MARPAT 136:200481

AB Novel thiazolyl peptides R1-Y-CH2CH(Q)CONH2 [Q is a residue of a thiazolyl peptide antibiotic, e.g., nocathiacin I or nosiheptide; Y = S, SO, SO2 or NR, where R = H, OH, alkoxy, alkanoyl, alkylcarbamoyl, etc.; R1 = 1-azabicyclo[2.2.2]oct-3-yl or N-oxide, [(CH2)2O]1-3(CH2)2R4' (R4' = OH, amino, phenylmethyl), or (un)substituted alkyl] were prepared for use in pharmaceutical compns. for the treatment of serious bacterial infections. Thus, a peptide prepared by Michael addition reaction of nocathiacin I with 1-methylpiperazine showed in vitro antibiotic activity 0.25, 0.125, and 0.5 μg/mL (MIC) against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis, resp.

IT 401826-04-8P 401826-37-7P 401826-74-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of water-soluble thiazolyl peptide derivs.)

RN 401826-04-8 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-amino-1-[[[2-(2,5-dioxo-1-pyrrolidinyl)ethyl]amino]methyl]-2-oxoethyl]-2-[(11S,14E,21S,22R,33S,49S)-9,10,11,12,13,14,19,20,21,22,29,30,32,33-tetradecahydro-3,29-dihydroxy-11-[(1R)-1-hydroxyethyl]-14-(1-methoxyethylidene)-9,12,19,30,40,48-hexaoxo-49-[[2,4,6-trideoxy-4-(dimethylamino)-3-C-methyl-α-L-lyxo-hexopyranosyl]oxy]-22,25-(ethanoxymethano)-8,5:18,15:37,34-trinitrilo-21,33-([2,4]-endo-thiazolomethanimino)-5H,15H,24H,34H-pyrido[3',2':20,21][1,28,8,18,24,4,11,14]dioxatrithiatriazacyclodotriacontino[30,31-b]indol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



RN 401826-37-7 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-1-[[methyl[2-(1-piperidinyl)ethyl]amino]methyl]-2-oxoethyl]-2-[(11S,14E,21S,22R,33S,49S)-9,10,11,12,13,14,19,20,21,22,29,30,32,33-tetradecahydro-3,29-dihydroxy-11-[(1R)-1-hydroxyethyl]-14-(1-methoxyethylidene)-9,12,19,30,40,48-hexaoxo-49-[[2,4,6-trideoxy-4-(dimethylamino)-3-C-methyl-α-L-lyxo-hexopyranosyl]oxy]-22,25-(ethanoxymethano)-8,5:18,15:37,34-trinitrilo-21,33-([2,4]-endo-thiazolomethanimino)-5H,15H,24H,34H-pyrido[3',2':20,21][1,28,8,18,24,4,11,14]dioxatrithiatriazacyclodotriacontino[30,31-b]indol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



RN 401826-74-2 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-amino-1-[[[3-(4-methyl-1-piperazinyl)propyl]amino]methyl]-2-oxoethyl]-2-[(11S,14E,21S,22R,33S,49S)-9,10,11,12,13,14,19,20,21,22,29,30,32,33-tetradecahydro-3,29-dihydroxy-11-[(1R)-1-hydroxyethyl]-14-(1-methoxyethylidene)-9,12,19,30,40,48-hexaoxo-49-[[2,4,6-trideoxy-4-(dimethylamino)-3-C-methyl-α-L-lyxo-hexopyranosyl]oxy]-22,25-(ethanoxymethano)-8,5:18,15:37,34-trinitrilo-21,33-([2,4]-endo-thiazolomethanimino)-5H,15H,24H,34H-pyrido[3',2':20,21][1,28,8,18,24,4,11,14]dioxatrithiatriazacyclodotriacontino[30,31-b]indol-2-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A



PAGE 4-A



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:643793 CAPLUS
DN 133:329128
TI Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of Nω-masked ornithine analogs
AU Itoh, Fumio; Yoshioka, Yoshio; Yukishige, Koichi; Yoshida, Sei; Ootsu, Koichiro; Akimoto, Hiroshi
CS Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan
SO Chemical & Pharmaceutical Bulletin (2000), 48(9), 1270-1280
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
OS CASREACT 133:329128
GI



I

AB Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates I [m = 2,3; n = 1-4; R = H, CO2Bu-t, CO2CH2Ph, CO(CH2)2CO2H, COCH:CHCO2H, COC6H4CO2H-2, COC6H4CO2H-4, 2-(1-pyrrolidinylcarbonyl)benzoyl, COC6H4OH-2, COC6H4(NHAc)-4, SO2C6H4Me-4, SO2C6H4CO2H-2, CONHC6H4F-4, CONHC6H4CO2H-3, CONHC6H4-3-B(OH)3, C6H4CO2H-3, 3-carboxy-2-naphthoyl, etc.] were synthesized and their inhibitory effects on dihydrofolate reductase (DHFR), the growth of murine fibrosarcoma Meth A cells, and methotrexate-resistant human CCRF-CEM cells were examined A free ornithine analog I (m = n = 3, R = H) did not strongly inhibit Meth A cell growth, whereas all Nω-substituted ornithine analogs (R = acyl, sulfonyl, carbamoyl, aryl) exhibited much more potent inhibitory activities against both DHFR and Meth A cell growth. In particular, compds. I [m = 2, n = 3,

R = COC6H4CO2H-2; m = 2, n = 3, R = 3-carboxy-2-naphthoyl; m = 2, n = 3, R = C6H4CO2H-3] also showed remarkable growth-inhibitory activities against methotrexate-resistant CCRF-CEM cells. These results demonstrate that the potent inhibitory activities of Nω-masked ornithine analogs against the growth of Meth A cells and methotrexate-resistant CCRF-CEM cells, results from effective uptake via reduced folate carrier and their potent DHFR inhibition.

IT 149009-83-6P 303957-87-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and antitumor activity of non-glutamate, ornithine-containing pyrrolo[2,3-d]pyrimidine antifolates)

RN 149009-83-6 CAPLUS
CN 2H-Isoindole-2-hexanoic acid, α-[[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]-1,3-dihydro-1,3-dioxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 303957-87-1 CAPLUS
CN 2H-Isoindole-2-hexanoic acid, α-[[4-[2-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]-1,3-dihydro-1,3-dioxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:260225 CAPLUS
DN 132:294010
TI Preparation of diaminopropionic acid derivatives as intracellular adhesion molecule-1 (ICAM-1) binding inhibitors
IN Fotouhi, Nader; Gillespie, Paul; Guthrie, Robert William; Pietranico-Cole, Sherrie Lynn; Yun, Weiya
PA F. Hoffmann-La Roche A.-G., Switz.
SO PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021920	A1	20000420	WO 1999-EP7620	19991012
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6331640	B1	20011218	US 1999-407534	19990929
CA 2344058	A1	20000420	CA 1999-2344058	19991012

	BR 9914602	A	20010703	BR 1999-14602	19991012
	EP 1121342	A1	20010808	EP 1999-953772	19991012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101038	T2	20010921	TR 2001-1038	19991012
	JP 2002527416	T	20020827	JP 2000-575829	19991012
	JP 3720709	B2	20051130		
	AU 766468	B2	20031016	AU 2000-10349	19991012
	MX 2001PA03284	A	20011011	MX 2001-PA3284	20010329
	ZA 2001002608	A	20020930	ZA 2001-2608	20010329
	US 2002052512	A1	20020502	US 2001-879700	20010612
	US 2004006236	A1	20040108	US 2003-349289	20030122
	US 6803384	B2	20041012		
	US 2005080119	A1	20050414	US 2004-945650	20040921
	US 7217728	B2	20070515		
	US 2007155671	A1	20070705	US 2007-703925	20070208
PRAI	US 1998-104120P	P	19981013		
	US 1999-407534	A3	19990929		
	WO 1999-EP7620	W	19991012		
	US 2001-879700	B3	20010612		
	US 2003-349289	A3	20030122		
	US 2004-945650	A3	20040921		
OS	MARPAT 132:294010				

GI



I

AB Diaminopropionic acid derivs. I [R1 = substituted 1-naphthyl, 4-indolyl, 4-benzimidazolyl, 4-benzodiazolyl, 4-benzotriazolyl, or phenyl; R2 = CHR3NHCO (R3 = H, carboxy, alkyl), CH2CH2CO, 1,2-cyclopropanediylcarbonyl, OCH2CO, CH:CHCHR3, CH2CH2CH(OH), CONHCHR3, or CH2NH-5,1-tetrazolediyl; U, V, W = H, halo, alkyl provided that U and V are not both hydrogen; X = CO, phenylalkylene, sulfonyl; Y = alkylene which may be substituted by amino or cycloalkyl, alkenylene, alkylenethio; Z = H, alkylthio, CO2H, CONH2, 1-adamantyl, diphenylmethyl, 3-[[(5-chloro-2-pyridinyl)amino]carbonyl]-2-pyrazinyl, hydroxy, phenylmethoxy, 2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]phenyl, [(2,6-dichlorophenyl)methoxy], Ph, (un)substituted cycloalkyl or aryl or fused ring system which may contain 0-3 heteroatoms; m, n = 0, 1] or their pharmaceutically acceptable salts or esters were prepared and are useful for treating rheumatoid arthritis, psoriasis, multiple sclerosis, Crohn's disease, ulcerative colitis, atherosclerosis, restenosis, pancreatitis, transplant rejection, delayed graft function and diseases of ischemia reperfusion injury, including acute myocardial infarction and stroke. Thus, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-(3-methoxybenzoylamino)-L-alanine was prepared by the solid-phase method and showed IC50 = 1.2 nM in the LFA-1 (lymphocyte function-associated

antigen-1)/ICAM-1 protein-protein assay.
IT 264273-57-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminopropionic acid derivs. as intracellular adhesion mol.-1 (ICAM-1) binding inhibitors)
RN 264273-57-6 CAPLUS
CN L-Alanine, N-[2-chloro-4-[[[(3-hydroxyphenyl)methyl]amino]carbonyl]benzoyl]-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:175829 CAPLUS
DN 132:208143
TI Preparation of peptides as NK-1 receptor antagonists
IN Groger, Karsten; Sisto, Alessandro
PA Menarini Ricerche S.p.A., Italy
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000014109	A1	20000316	WO 1999-EP6541	19990906
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	IT 1304898	B1	20010405	IT 1998-FI201	19980908
	AU 9957457	A1	20000327	AU 1999-57457	19990906
PRAI	IT 1998-FI201	A	19980908		
	WO 1999-EP6541	W	19990906		

OS MARPAT 132:208143
AB Peptides R1(CH2)nCONHCH[(CH2)pR2]CONHCHR3CONR4R5 [(S)-configuration at

CHR3; n = 0-3; p = 0-4; R1 = a basic moiety chosen from an amino or heterocyclyl group, aryl or arylalkyl which can be substituted on the aromatic moiety; R2 = R6(CH2)m-X1-, where m = 0-3; R6 = amino group, heterocyclyl, aryl or arylalkyl which can be substituted on the aromatic moiety; X1 = CONH or NHCO; R3 = naphthylmethyl, halobenzyl, indolylmethyl; R4 = aryl or arylalkyl which can be substituted on the aromatic moiety; R5 = H, Me] (with provisos) were prepared as NK-1 receptor antagonists. Thus, Nα-{Nα-[(1H)indol-3-ylcarbonyl]-L-asparaginyl[β-N-[2-(morpholin-4-yl)ethyl]]}-L-[3-(3,4-dichlorophenyl)alanine]-N-methyl-N-(4-bromobenzyl)amide, prepared by step-wise couplings in solution, showed pKi = 9.3 for inhibition of [3H]SP binding to IM9 cells.

IT 260809-08-3P 260809-12-9P 260809-13-0P
260809-14-1P 260809-16-3P 260809-17-4P
260809-18-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as NK-1 receptor antagonists)

RN 260809-08-3 CAPLUS

CN L-Alaninamide, N-(1H-indol-3-ylcarbonyl)-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]-L-alanyl-N-methyl-N-[(4-methylphenyl)methyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260809-12-9 CAPLUS

CN L-Alaninamide, N-(1H-indol-3-ylcarbonyl)-3-[[3-(4-methyl-1-piperazinyl)-1-oxopropyl]amino]-L-alanyl-N-methyl-N-[(4-methylphenyl)methyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260809-13-0 CAPLUS
CN L-Alaninamide, N-(1H-indol-3-ylcarbonyl)-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]-L-alanyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260809-14-1 CAPLUS
CN L-Tryptophanamide, N-(1H-indol-3-ylcarbonyl)-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]-L-alanyl-N-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260809-16-3 CAPLUS
CN L-Alaninamide, N-(1H-indol-3-ylcarbonyl)-3-[[1-oxo-3-(1-piperidinyl)propyl]amino]-D-alanyl-N-methyl-N-[(4-methylphenyl)methyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260809-17-4 CAPLUS
CN L-Alaninamide, N-(1H-indol-3-ylcarbonyl)-3-[[3-(4-methyl-1-piperazinyl)-1-oxopropyl]amino]-D-alanyl-N-methyl-N-[(4-methylphenyl)methyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260809-18-5 CAPLUS
CN L-Alaninamide, N-(1H-indol-3-ylcarbonyl)-3-[(1-piperazinylacetyl)amino]-D-alanyl-N-methyl-N-[(4-methylphenyl)methyl]-3-(2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:53583 CAPLUS
DN 126:70149
TI Hydrochlorides of 1-phenyl-1-(p-nitrobenzoyl amino)-5-(n-piperidino)- or (n-diethylamino)pentanes having antiarrhythmic and antifibrillation activity
IN Mashkovskij, M. D.; Glushkov, R. G.; Skachilova, S. Ya.; Dorodnikova, E. V.; Rozenshtraukh, L. V.; Voronin, V. G.; Zheltukhin, N. K.; Anyukhovskij, E. P.; Nesterenko, V. V.; Cherkasova, E. M.

PA Tsentr Po Khimii Lekarstvennykh Sredstv, USSR; Vsesoyuznyj Nauchnyj Tsentr Po Bezopasnosti Biologicheski Aktivnykh Veshchestv; Vsesoyuznyj Kardiologicheskij Nauchnyj Tsentr Amn Sssr
SO U.S.S.R.
From: Izobreteniya 1996, (6), 261.
CODEN: URXXAF
DT Patent
LA Russian
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI SU 1833612	A3	19960227	SU 1987-4359472	19871208
PRAI SU 1987-4359472		19871208		

AB Title only translated.
IT 185384-75-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Hydrochlorides of 1-phenyl-1-(p-nitrobenzoyl amino)-5-(n-piperidino)- or (n-diethylamino)pentanes having antiarrhythmic and antifibrillation activity)
RN 185384-75-2 CAPLUS
CN Benzamide, 4-nitro-N-[1-phenyl-5-(1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:494173 CAPLUS
DN 125:143330
TI Peptide compounds for prevention and/or treatment of nitric oxide (NO)-mediated diseases
IN Itoh, Yoshikuni; Iwamoto, Toshiro; Yatabe, Takumi; Hamashima, Hitoshi; Inoue, Takayuki; Hashimoto, Seiji; Oku, Teruo
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 739 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9616981	A2	19960606	WO 1995-JP2428	19951129
WO 9616981	A3	19960906		

W: AU, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9539937 A 19960619 AU 1995-39937 19951129
EP 796270 A2 19970924 EP 1995-938602 19951129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
ZA 9510201 A 19960625 ZA 1995-10201 19951130
US 5932737 A 19990803 US 1997-849076 19970530
PRAI GB 1994-24408 A 19941202
GB 1995-4891 A 19950310
GB 1995-10042 A 19950518
WO 1995-JP2428 W 19951129
OS MARPAT 125:143330
GI



I

AB Peptides WA1NR8CH(A2T)CONR9CH(A3R3)R4 [W = alkyl, (un)substituted aryl or fluorenyl, etc.; A1 = alkylene, NHCO, CO, CS, SO2; A2 = alkylene; T = H, aryl, heterocyclyl, OH, etc.; R8 = H, alkyl; R8 may link with A2T to form CH2C6H4CH2-o (Q); A3 = bond, alkylene; R3 = H, aryl, OH, etc.; R9 = H, alkyl or may link with A3R3 to form Q; R4 = CO2H, protected carboxy, carboxamido, etc. or CH(A3R3)R4 = N-alkyl-2-oxoquinoline moiety] or their pharmaceutically acceptable salts were prepared for use as medicaments. Thus, dipeptide I was prepared by acylation of aspartylphenylalaninamide derivative with 2-benzofurancarboxylic acid. I and six other peptides showed 100% inhibition of NO production in tests of murine macrophage cells.
IT 179881-40-4P 179881-43-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of peptides for prevention and/or treatment of nitric oxide-mediated diseases)
RN 179881-40-4 CAPLUS
CN L-Phenylalaninamide, N-(2-benzofuranylcarbonyl)-O-(4-pyridinylacetyl)-L-seryl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179881-43-7 CAPLUS
CN L-Phenylalaninamide, N-(2-benzofuranylcarbonyl)-O-[1-oxo-3-(1-piperidinyl)propyl]-L-seryl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:904875 CAPLUS
DN 124:240
TI Search for antiarrhythmic drugs among 1,5-diaminopentane derivatives
AU Mashkovskii, M. D.; Glushkov, R. G.; Dorodnikova, E. V.; Yuzhakov, S. D.
CS TSKhLS, VNIKhFI, Moscow, Russia
SO Khimiko-Farmatsevticheskii Zhurnal (1995), 29(3), 27-31
CODEN: KHFZAN; ISSN: 0023-1134
PB Meditsina
DT Journal
LA Russian
AB Most of the 28 1,5-diaminopentanes tested showed antiarrhythmic activity in rats. Structure-activity relations are briefly discussed.
IT 171203-85-3 171203-86-4 171203-87-5
171203-88-6 171203-89-7 171203-90-0
171203-91-1 171203-92-2 171203-93-3
171203-94-4 171203-95-5 171203-96-6
171203-99-9 171204-00-5 171204-01-6
171204-02-7 171204-03-8 171204-04-9

171204-05-0 171204-06-1 171204-07-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(search for antiarrythmic drugs among 1,5-diaminopentane derivs.)

RN 171203-85-3 CAPLUS
CN Benzamide, N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171203-86-4 CAPLUS
CN 3-Pyridinecarboxylic acid, compd. with N-[1-phenyl-5-(1-piperidinyl)pentyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171203-85-3
CMF C23 H30 N2 O



CM 2

CRN 59-67-6
CMF C6 H5 N O2



RN 171203-87-5 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, compd. with N-[1-phenyl-5-(1-piperidinyl)pentyl]benzamide (1:1) (CA INDEX NAME)

CM 1

CRN 171203-85-3
CMF C23 H30 N2 O



CM 2

CRN 65-86-1
CMF C5 H4 N2 O4



RN 171203-88-6 CAPLUS
CN Benzamide, N-[1-(4-methylphenyl)-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171203-89-7 CAPLUS
CN Benzamide, N-[1-(4-chlorophenyl)-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171203-90-0 CAPLUS
CN Benzamide, 4-nitro-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171203-91-1 CAPLUS
CN Benzamide, N-[1-(4-methylphenyl)-5-(1-piperidinyl)pentyl]-4-nitro- (CA INDEX NAME)



RN 171203-92-2 CAPLUS
CN Benzamide, N-methyl-4-nitro-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171203-93-3 CAPLUS
CN Benzamide, N-[1-[4-(1-methylethyl)phenyl]-5-(1-piperidinyl)pentyl]-4-nitro- (CA INDEX NAME)



RN 171203-94-4 CAPLUS
CN Benzamide, N-[1-(4-methoxyphenyl)-5-(1-piperidinyl)pentyl]-4-nitro- (CA INDEX NAME)



RN 171203-95-5 CAPLUS
CN Benzamide, N-[1-(3,4-dimethylphenyl)-5-(1-piperidinyl)pentyl]-4-nitro- (CA INDEX NAME)



RN 171203-96-6 CAPLUS
CN Benzamide, N-[1-(3,4-dimethoxyphenyl)-5-(1-piperidinyl)pentyl]-4-nitro- (CA INDEX NAME)



RN 171203-99-9 CAPLUS
CN Benzamide, N-[5-(4-methyl-1-piperazinyl)-1-phenylpentyl]-4-nitro-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 171204-00-5 CAPLUS
CN Benzamide, 4-bromo-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171204-01-6 CAPLUS
CN Benzamide, 2,4-dinitro-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171204-02-7 CAPLUS
CN Benzamide, 2-chloro-5-nitro-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171204-03-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171204-04-9 CAPLUS
CN Benzamide, 3,4,5-trimethoxy-N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171204-05-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[1-phenyl-5-(1-piperidinyl)pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)





RN 171204-06-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-phenyl-5-(1-piperidinyl)pentyl]- (CA INDEX NAME)



RN 171204-07-2 CAPLUS
CN 2,6-Pyridinedicarboxamide, N,N'-bis[1-phenyl-5-(1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:605936 CAPLUS
DN 121:205936
TI Synthesis and Biological Activity of Nω-Hemiphthaloyl-α,ω-diaminoalkanoic Acid Analogs of Aminopterin and 3',5-Dichloroaminopterin
AU Rosowsky, Andre; Bader, Henry; Wright, Joel E.; Keyomarsi, Khandan; Matherly, Larry H.
CS Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
SO Journal of Medicinal Chemistry (1994), 37(14), 2167-74
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I

AB Analogs of Nα-(4-amino-4-deoxypteroyl)-Nδ-(hemiphthaloyl)-L-ornithine (I) (PT523) with 3',5'-dichloro substitution in the p-aminobenzoyl moiety or with one less or more CH2 group in the amino acid moiety were synthesized and tested as inhibitors of dihydrofolate reductase (DHFR) activity and cell growth. Replacement of L-ornithine in I by L-2,4-diaminobutanoic acid or L-lysine did not decrease binding to human recombinant DHFR but resulted in some loss of activity against SCC25 human and SCC VII murine squamous cell carcinoma and against MCF-7 human breast carcinoma in culture. PT523 was several times more potent than

methotrexate (MTX), aminopterin (AMT), or trimetrexate (TMQ). 3',5'-Dichloro substitution did not decrease either DHFR binding or cytotoxicity. A new synthetic route to I from 2,4-diamino-6-(hydroxymethyl)pteridine and Nα-(4-aminobenzoyl)-Nδ-phthaloyl-L-ornithinine Me ester was investigated but was not superior to previously described methods. In comparative expts. on the ability of PT523 and MTX to competitively inhibit the influx of(6R)-5,10-dideazatetrahydrofolate (DDATHF, lometrexol), used a surrogate for MTX and reduced folates, the Ki of PT523 was lower than that of MTX in both wild-type CCRF-CEM human leukemic lymphoblasts and the transport- and polyglutamylation-defective subline CEM/MTX. The CCRF-CEM cells were 10-fold more sensitive to PT523 than to MTX, whereas the CEM/MTX cells were 240-fold more sensitive. However, in contrast to other MTX-resistant cells where collateral sensitivity to PT523 has been seen. CEM/MTX cells still showed substantial cross resistance to PT523 which may reflect an unusual heightened ability to utilize exogenous folic acid. The good correlation observed with both cell lines between the cytotoxicity of PT523 and MTX and the ability to inhibit DDATHF influx supported the view that PT523 and MTX share, at least in part, a common protein carrier for membrane transport.

IT 158090-66-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, saponification, and imide ring opening of)

RN 158090-66-5 CAPLUS

CN 2H-Isoindole-2-hexanoic acid, α-[[4-[[(2,4-diamino-6-pteridinyl)methyl]formylamino]benzoyl]amino]-1,3-dihydro-1,3-dioxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:626417 CAPLUS

DN 119:226417

TI Preparation of condensed pyrimidinylacyl amino acids as neoplasm inhibitors

IN Akimoto, Hiroshi; Ootsu, Koichiro; Itoh, Fumio

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	EP 530537	A1	19930310	EP 1992-113523	19920807
	EP 530537	B1	19970108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5403843	A	19950404	US 1992-926170	19920807
	AT 147386	T	19970115	AT 1992-113523	19920807
	CA 2075787	A1	19930213	CA 1992-2075787	19920811
	JP 06049069	A	19940222	JP 1992-214142	19920811
	JP 3376479	B2	20030210		
PRAI	JP 1991-202042	A	19910812		
	JP 1992-71513	A	19920327		
	JP 1992-145851	A	19920605		

OS CASREACT 119:226417; MARPAT 119:226417

GI For diagram(s), see printed CA Issue.

AB Title compds. [I; ring A = (substituted) (hydrogenated) 5-membered ring; B = (substituted) divalent 5- or 6-membered homo- or heterocyclic group; X = amino, OH, SH; Y = H, halo, C-, N-, O-, or S-bonded group; Z = (substituted) (heteroatom-containing) divalent group having ≤5 atoms; W = NRCO; R = H, (substituted) alkyl; R1 = (substituted) cyclic or chain-like group; or RR1 = atoms to form a 3-13 membered ring CO2R2 = optionally esterified carboxyl group; p = 1-4; with provisos], were prepared Thus, Nα-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-Nδ-phthaloyl-L-ornithine Me ester [prepared by condensation of the corresponding benzoic acid with Nδ-phthaloyl-L-ornithine Me ester.HCl using di-Et cyanophosphate and Et3N in DMF] was saponified to give Nα-[4-[2-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-Nδ-hemiphthaloyl-L-ornithine. This inhibited proliferation of A549 cells with IC50 = 0.0012 μg/mL.

IT 149009-83-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as neoplasm inhibitor)

RN 149009-83-6 CAPLUS

CN 2H-Isoindole-2-hexanoic acid, α-[[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]-1,3-dihydro-1,3-dioxo-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L6 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:603167 CAPLUS
DN 119:203167
TI Substituted 1-phenyl-1-benzoylamino-5-aminopentanes, their preparation and use
IN Mashkovsky, Mikhail D.; Glushkov, Robert G.; Skachilova, Sofiya Y.; Dorodnikova, Elena V.; Rosenshtraukh, Leonid V.; Voronin, Vasily G.; Zheltukhin, Nikolai K.; Anjukhovsky, Evgenii P.; Nesterenko, Vladislav V.; et al.
PA USSR
SO Can. Pat. Appl., 12 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2073833	A1	19930301	CA 1992-2073833	19920714
EP 535256	A1	19930407	EP 1991-114635	19910830
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
HU 62854	A2	19930628	HU 1992-2316	19920714
ZA 9205237	A	19940114	ZA 1992-5237	19920714
AU 9220407	A	19930304	AU 1992-20407	19920720
AU 648422	B2	19940421		
BR 9202849	A	19930406	BR 1992-2849	19920723
JP 06192197	A	19940712	JP 1992-226829	19920826
PRAI EP 1991-114635	A	19910830		

OS CASREACT 119:203167; MARPAT 119:203167
GI

I

AB The title compds. (I; R1 = halo, NO2, C1-4 aminoacyl, sulfonamido; R2, R3 = C1-5 alkyl or R2R3 = C3-6 alkylene) and their optically active isomers and their physiol. tolerated acids are prepared as antiarrhythmic and

antifibrillatory compds. [e.g., (±)-I (R1 = p-NO2, R2 = R3 = Et).HCl [(±)-II]; (+)- and (-)-II]. Thus, Et2N(CH2)4CH(NH2)Ph.HCl in 10% aqueous NaOH-Me2CO is treated with p-O2NC6H4COCl to give I (R1 = p-NO2, R2 = R3 = Et); this in Me2CO with HCl in Me2CHOH gives (±)-II. Dosages are given.

IT 150492-00-5 150492-01-6 185384-75-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation as antiarrythmic)

RN 150492-00-5 CAPLUS
CN Benzamide, 4-bromo-N-[1-phenyl-5-(1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 150492-01-6 CAPLUS
CN Benzamide, 4-(acetylamino)-N-[1-phenyl-5-(1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185384-75-2 CAPLUS
CN Benzamide, 4-nitro-N-[1-phenyl-5-(1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:229364 CAPLUS
DN 114:229364
TI Synthesis of α,ω-diamino acids via amidocarbonylation reaction: novel synthesis of lysine, ornithine, and their analogs.
AU Amino, Yusuke; Izawa, Kunisuke
CS Cent. Res. Lab., Ajinomoto Co., Inc., Kawasaki, 210, Japan
SO Bulletin of the Chemical Society of Japan (1991), 64(2), 613-19
CODEN: BCSJA8; ISSN: 0009-2673
DT Journal
LA English
OS CASREACT 114:229364
AB α,ω-Diamino acid derivs., and as lysine and ornithine, were synthesized via cobalt-catalyzed amidocarbonylation of ω-(phthalimido)alkanals in good yield. The phthalimido group was stable to the conditions of amidocarbonylation. The hydroformylation-amidocarbonylation of N-phthaloyl-β,γ- and N-phthaloyl-γ,δ-unsatd. amines proceeds very nicely to give α,ω-diamino acids with good selectivity. Selective deprotection of α-N-acyl-ω-N-phthaloyl α,ω-amino acids was achieved using hydrazine for the N-phthaloyl group and aminoacylase for the N-acetyl group to afford the optically active α,ω-diamino acid.
IT 133787-09-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 133787-09-4 CAPLUS
CN 2H-Isoindole-2-hexanoic acid, α-(benzoylamino)-1,3-dihydro-1,3-dioxo-, methyl ester (CA INDEX NAME)



L6 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1973:72548 CAPLUS
DN 78:72548
OREF 78:11545a,11548a
TI N-Phthaloylation of chloro- and hydroxy-2-amino acids
AU Clarke, S.; Hider, R. C.; John, D. I.
CS Dep. Biochem., Yale Univ., New Haven, CT, USA
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1973), (3), 230-4
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 78:72548
AB N-Phthaloylation of 4-chloro- and 4-hydroxy-2-amino acids was achieved in 40-88% yield with N-(ethoxycarbonyl)phthalimide (I) (1.1 equivalent) in Me2SO containing Et3N; thus prepared were the N-phthaloyl derivs. of Cl(CH2)2-CH(NH2)CO2Me) (II), the Me esters of 3-chloroalanine, and 4-chloronorvaline, and the lactone of 4-hydroxyleucine. Phthaloylation of 4-chlorolysine Me ester gave 26% of the N6-phthaloyl and N,N'-diphthaloyl derivs. Similarly, phthaloylation of the lactone of 4-hydroxylysine gave a mixture of the N6-phthaloyl and N,N'-diphthaloyl derivs. The rates of cyclization of the intermediates o-(EtO2CNHCO)C6H4CONHR (R = Cl(CH2)2-CHCO2Me, PhCH2, Bu) isolated from the reactions of I with II, PhCH2NH2, and BuNH2, resp., confirmed the mechanism proposed for aminolysis of I.
IT 39739-20-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39739-20-3 CAPLUS
CN 2H-Isoindole-2-hexanoic acid, α-(benzoylamino)-γ-chloro-1,3-dihydro-1,3-dioxo-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1963:33274 CAPLUS
DN 58:33274
OREF 58:5631d-g
TI 1,5,9-Triaminononane derivatives
AU Ose, Shinsuke; Takamatsu, Hideji; Saeki, Takeji
CS Dai-nippon Pharm. Co., Osaka
SO Yakugaku Zasshi (1962), 82, 1197-9
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal

LA Unavailable
AB A solution of 21 g. 1,9-dibromo-5-aminononane-HCl in C6H6 is refluxed with 12 g. BzCl 16 hrs. to give 20.1 g. 1,9-dibromo-5-benzamidononane (I), m. 82-3° (ligroine). A solution of I in C6H6 is refluxed with Me2NH 15 hrs. to give 1,9-bis(diethylamino)-5-benzamidononane (II), m. 82-3°. Similarly prepared are the following [R(CH2)4]2CHNHBz (R and m.p. given): piperidino, 90-2°; morpholino, 98-101°; pyrrolidino, 89-91°; 1,2,3,4-tetrahydro-2-isoquinolyl, 111-12°; 1,2,3,4-tetrahydro-1-quinolyl, 134-5°. II is heated with 20 times excess H3PO4 at 180-5° 12 hrs. to give 1,9-bis(diethylamino)-5-aminonane (III), sirupy. Similarly are prepared the following [R(CH2)4]2CHNH2R (R and b.p./mm. given): piperidino, 186-7°/2; morpholino, 200-4°/3.5; pyrrolidino, 162-3°/1; 1,2,3,4-tetrahydro-2-isoquinolyl, sirupy; 1,2,3,4-tetrahydro-1-quinolyl, sirupy. III is heated with HCHO and HCO2H, made alkaline with NaOH, and extracted with Et2O to give 1,9-bis(diethylamino)-5-dimethylaminononane (IV), b1 118°; trihydrochloride m. 247°. Similarly are prepared the following [R(CH2)4]2CHNMe2 (R, b.p./mm., and m.p. of trihydrochloride given): piperidino, 177°/1, 256°; morpholino, 185°/2, 254-6°; pyrrolidino, 158-160°/1, 230-1°; 1,2,3,4-tetrahydro-2-isoquinolyl, 250°/0.4, 115-18°. IV is allowed to stand with MeBr in EtOH to give the corresponding methobromide, m. 267-8°(EtOH). Similarly prepared are following [R2MeN+(CH2)4]2CHN+ Me3.3Br- (R2N and m.p. given): piperidino, 280-1°; morpholino, 259-60°; pyrrolidino, 277-8°; 1,2,3,4-tetrahydro-2-isoquinolyl, 232-3°; 1,2,3,4-tetrahydro-1-quinolyl, 133-6°.
IT 96173-74-9P, Benzamide, N-[5-piperidino-1-(4-piperidinobutyl)pentyl]- 96586-63-9P, Benzamide, N-[5-(1-pyrrolidinyl)-1-[4-(1-pyrrolidinyl)butyl]pentyl]- 97573-27-8P, Benzamide, N-[5-(3,4-dihydro-2(1H)-isoquinolyl)-1-[4-(3,4-dihydro-2(1H)-isoquinolyl)butyl]pentyl]- 97573-28-9P, Benzamide, N-[5-(3,4-dihydro-1(2H)-quinolyl)-1-[4-(3-4-dihydro-1(2H)-quinolyl)butyl]pentyl]-
RL: PREP (Preparation)
(preparation of)
RN 96173-74-9 CAPLUS
CN Benzamide, N-[5-piperidino-1-(4-piperidinobutyl)pentyl]- (7CI) (CA INDEX NAME)



RN 96586-63-9 CAPLUS
CN Benzamide, N-[5-(1-pyrrolidinyl)-1-[4-(1-pyrrolidinyl)butyl]pentyl]- (CA INDEX NAME)



RN 97573-27-8 CAPLUS
CN Benzamide, N-[5-(3,4-dihydro-2(1H)-isoquinolyl)-1-[4-(3,4-dihydro-2(1H)-isoquinolyl)butyl]pentyl]- (7CI) (CA INDEX NAME)



RN 97573-28-9 CAPLUS
CN Benzamide, N-[5-(3,4-dihydro-1(2H)-quinolyl)-1-[4-(3,4-dihydro-1(2H)-quinolyl)butyl]pentyl]- (7CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	122.99	301.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-17.16	-17.16

FILE 'CAOLD' ENTERED AT 12:16:37 ON 27 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l5
L7 1 L5

=> d l7 bib hitstr

L7 ANSWER 1 OF 1 CAOLD COPYRIGHT 2007 ACS on STN
AN CA58:5631d CAOLD
TI 1,5,9-triaminononane derivs.
AU Ose, Shinsuke; Takamatsu, H.; Saheki, T.
TI catalytic dehydrogenation of aldehydecollidine
AU Oga, Taijiro
IT 96173-74-9 96586-63-9 97573-27-8
97573-28-9
RN 96173-74-9 CAOLD
CN Benzamide, N-[5-piperidino-1-(4-piperidinobutyl)pentyl]- (7CI) (CA INDEX NAME)



RN 96586-63-9 CAOLD
CN Benzamide, N-[5-(1-pyrrolidinyl)-1-[4-(1-pyrrolidinyl)butyl]pentyl]- (CA INDEX NAME)



RN 97573-27-8 CAOLD
CN Benzamide, N-[5-(3,4-dihydro-2(1H)-isoquinolyl)-1-[4-(3,4-dihydro-2(1H)-isoquinolyl)butyl]pentyl]- (7CI) (CA INDEX NAME)



RN 97573-28-9 CAOLD
CN Benzamide, N-[5-(3,4-dihydro-1(2H)-quinolyl)-1-[4-(3,4-dihydro-1(2H)-quinolyl)butyl]pentyl]- (7CI) (CA INDEX NAME)



=> file chemcats

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.47	305.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-17.16

FILE 'CHEMCATS' ENTERED AT 12:16:58 ON 27 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE LAST UPDATED 22 DECEMBER 2007 (20071222/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPB, HELP SPC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPQZ. For the list of current catalogs, enter HELP CTA, HELP CTB, HELP CTC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising

out of the use of this database.

CHEMCATS now contains more than 17 million records. See HELP CONTENT
and NEWS FILE for details.

=> s l5
L8 15 L5

=> d l8 1-15 ide

L8 ANSWER 1 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2038939899 CHEMCATS
Catalog Name (CO): ChemDiv Discovery Chemistry Collection Public Database
Publication Date (PD): 2 Oct 2007
Order Number (ON): 6186-3776
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 2 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2037170526 CHEMCATS
Catalog Name (CO): New Chemistry Horizons Laboratories Screening Library
Publication Date (PD): 8 Nov 2007
Order Number (ON): NCHSC2-79979
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 3 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2036468702 CHEMCATS
Catalog Name (CO): Ambinter Stock Screening Collection
Publication Date (PD): 1 Jun 2007
Order Number (ON): AKI-STT-00114311
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
Synonym (CN): Also sold under Ambinter Order Number(s): STK135578
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 4 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2036286427 CHEMCATS
Catalog Name (CO): Ambinter Stock Screening Collection
Publication Date (PD): 1 Jun 2007
Order Number (ON): STOCK1S-00425
Chemical Name (CN): Benzamide, N-[1-phenyl-5-(1-piperidinyl)pentyl]-
CAS Registry No. (RN): 171203-85-3
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 5 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2031192446 CHEMCATS
Catalog Name (CO): Aurora Screening Library
Publication Date (PD): 6 Sep 2007
Order Number (ON): kbs-008261
Chemical Name (CN): Benzamide, N-[1-phenyl-5-(1-piperidinyl)pentyl]-
CAS Registry No. (RN): 171203-85-3
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 6 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2028002259 CHEMCATS
Catalog Name (CO): MicroChemistry Screening Collection
Publication Date (PD): 25 Apr 2007
Order Number (ON): 281369
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 7 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2027695637 CHEMCATS
Catalog Name (CO): Princeton Gold Collection I
Publication Date (PD): 13 Jul 2007
Order Number (ON): OSSK_540709
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY

Structure :



L8 ANSWER 8 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2026069766 CHEMCATS
Catalog Name (CO): Aurora Screening Library
Publication Date (PD): 6 Sep 2007
Order Number (ON): kina-0064310
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 9 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2023243378 CHEMCATS
Catalog Name (CO): Scientific Exchange Product List
Publication Date (PD): 18 May 2007
Order Number (ON): M-106500
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 10 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2021307126 CHEMCATS
Catalog Name (CO): AKos Screening Library
Publication Date (PD): 7 Feb 2006
Order Number (ON): AKL-P-1106500
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
Synonym (CN): Also sold under AKos Order Number(s): STT-00114311, OWH-2041105
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 11 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2020286708 CHEMCATS
Catalog Name (CO): Interchim Intermediates
Publication Date (PD): 9 Jul 2007
Order Number (ON): STOCK3S-45083
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
Synonym (CN): Also sold under Interchim Order Number(s): AJ-292/41685861, STK135578
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 12 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2020172785 CHEMCATS
Catalog Name (CO): Interchim Intermediates
Publication Date (PD): 9 Jul 2007
Order Number (ON): STOCK1S-00425
Chemical Name (CN): Benzamide, N-[1-phenyl-5-(1-piperidinyl)pentyl]-
CAS Registry No. (RN): 171203-85-3
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 13 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2017056336 CHEMCATS
Catalog Name (CO): Compounds For Screening
Publication Date (PD): 6 Nov 2007
Order Number (ON): AJ-292/41685861
Chemical Name (CN): 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl (1,3-dioxooctahydro-2H-isoindol-2-yl)acetate
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 14 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2014902440 CHEMCATS
Catalog Name (CO): Vitas-M Screening Collection
Publication Date (PD): 7 Jun 2007
Order Number (ON): STK135578
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



L8 ANSWER 15 OF 15 CHEMCATS COPYRIGHT 2007 ACS on STN
Accession No. (AN): 2010420418 CHEMCATS
Catalog Name (CO): Interbioscreen Compound Library
Publication Date (PD): 5 Oct 2007
Order Number (ON): STOCK3S-45083
Chemical Name (CN): 2H-Isoindole-2-acetic acid, octahydro-1,3-dioxo-, 2-methyl-2-[(10H-phenothiazin-10-ylcarbonyl)amino]propyl ester
CAS Registry No. (RN): 511513-88-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.63	335.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-17.16

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:17:35 ON 27 DEC 2007